Lifelong prevention of atherosclerotic cardiovascular disease (ASCVD) through LDL-C control - Means and cost/benefit of sustained very low lifetime LDL-C targets

被引：1
|
作者：
Dalakoti, Mayank [1 ,2 ,3 ]
Virani, Salim [4 ,5 ,6 ]
机构：
[1] Natl Univ Heart Ctr, Dept Cardiol, Singapore, Singapore
[2] Ng Teng Fong Gen Hosp, Dept Med, Singapore, Singapore
[3] Univ Cambridge, Dept Publ Hlth & Primary Care, Cambridge, England
[4] Aga Khan Univ, Dept Med, Karachi, Pakistan
[5] Texas Heart Inst, Houston, TX USA
[6] Baylor Coll Med, Sect Cardiovasc Res, Houston, TX USA
来源：
AMERICAN JOURNAL OF PREVENTIVE CARDIOLOGY | 2024年 / 19卷
关键词：
Keywords; LDL-C; Primary prevention; Primordial prevention; Preventive cardiology; Lipids; CHOLESTEROL; MANAGEMENT;
D O I：
10.1016/j.ajpc.2024.100720
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Inclisiran: A New Strategy for LDL-C Lowering and Prevention of Atherosclerotic Cardiovascular Disease
    Albosta, Michael S.
    Grant, Jelani K.
    Taub, Pam
    Blumenthal, Roger S.
    Martin, Seth S.
    Michos, Erin
    VASCULAR HEALTH AND RISK MANAGEMENT, 2023, 19 : 421 - 431
  • [2] Transient very low LDL-C levels: a legacy effect for cardiovascular prevention?
    Genest, Jacques
    EUROPEAN HEART JOURNAL, 2023, 44 (16) : 1418 - 1420
  • [3] The LDL-C/ApoB ratio predicts major cardiovascular events in patients with established atherosclerotic cardiovascular disease
    Drexel, Heinz
    Larcher, Barbara
    Mader, Arthur
    Vonbank, Alexander
    Heinzle, Christine F.
    Moser, Berthold
    Zanolin-Purin, Daniela
    Saely, Christoph H.
    ATHEROSCLEROSIS, 2021, 329 : 44 - 49
  • [4] The importance of LDL-C lowering in atherosclerotic cardiovascular disease prevention: Lower for longer is better
    Mhaimeed, Omar
    Burney, Zain A.
    Schott, Stacey L.
    Kohli, Payal
    Marvel, Francoise A.
    Martin, Seth S.
    AMERICAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2024, 18
  • [5] LDL-C Targets in Secondary Prevention: How Low Should We Go?
    Bayoumy, Karim
    Gaber, Mohammed
    Mani, Preethi
    Puri, Rishi
    Donnellan, Eoin
    Cho, Leslie
    Clark, Donald, III
    Martin, Seth S.
    Elshazly, Mohamed B.
    CURRENT CARDIOVASCULAR RISK REPORTS, 2019, 13 (08)
  • [6] Cardiovascular Outcomes of Early LDL-C Goal Achievement in Patients with Very-High-Risk ASCVD
    Kim, Ah-Ram
    Han, Ji Ye
    Kim, Minkyoung
    Lee, Hojoon
    Baek, Yeon-Hee
    Ahn, Imjin
    Kang, Hee Jun
    Oh, Ji Seon
    Kim, Ju Hyeon
    Kwon, Osung
    Jun, Tae Joon
    Kwon, Sun U.
    Kim, Young-Hak
    CARDIOLOGY AND THERAPY, 2025, 14 (01) : 101 - 115
  • [7] The Expected Cardiovascular Benefit of Plasma Cholesterol Lowering with or Without LDL-C Targets in Healthy Individuals at Higher Cardiovascular Risk
    Yue Cesena, Fernando Henpin
    Laurinavicius, Antonio Gabriele
    Valente, Viviane A.
    Conceicao, Raquel D.
    Santos, Raul D.
    Bittencourt, Marcio S.
    ARQUIVOS BRASILEIROS DE CARDIOLOGIA, 2017, 108 (06) : 518 - 525
  • [8] Time for new low density lipoprotein cholesterol (LDL-C) targets?
    Daskalopoulou, Stella S.
    Mikhailidis, Dimitri P.
    EXPERT OPINION ON PHARMACOTHERAPY, 2017, 18 (15) : 1539 - 1541
  • [9] Sweetless'n low LDL-C targets for PCSK9 treatment
    Gencer, Baris
    Mach, Francois
    EUROPEAN HEART JOURNAL, 2015, 36 (19) : 1146 - 1148
  • [10] LDL-C does not cause cardiovascular disease: a comprehensive review of the current literature
    Ravnskov, Uffe
    de Lorgeril, Michel
    Diamond, David M.
    Hama, Rokuro
    Hamazaki, Tomohito
    Hammarskjold, Bjorn
    Hynes, Niamh
    Kendrick, Malcolm
    Langsjoen, Peter H.
    Mascitelli, Luca
    McCully, Kilmer S.
    Okuyama, Harumi
    Rosch, Paul J.
    Schersten, Tore
    Sultan, Sherif
    Sundberg, Ralf
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2018, 11 (10) : 959 - 970
12345